<DOC>
	<DOC>NCT00728546</DOC>
	<brief_summary>Apply the information of NAT2 genotyping into the re-challenge protocol of INH titration in patients with anti-TB medication induced hepatitis.</brief_summary>
	<brief_title>NAT2 in Re-challenge of INH in Patients With Hepatitis</brief_title>
	<detailed_description>adjusting INH dose according to NAT2 genotyping and serum concentration of INH.</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<criteria>Older than 18 yearsold Taken INH for more than 1 week Abnormal liver function Exclusion criteria: Rule out the INH induced liver abnormality Existing reasons to cause liver abnormality other than TBmedication Taking drugs which interact with INH</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>tuberculosis</keyword>
	<keyword>isoniazid</keyword>
	<keyword>Arylamine N-acetyl transferase</keyword>
	<keyword>genotyping</keyword>
	<keyword>hepatotoxicity</keyword>
	<keyword>pharmacogenetics</keyword>
</DOC>